ENANTA PHARMACEUTICALS, INC Restricted Cash, Current
ENANTA PHARMACEUTICALS, INC (ENTA) had Restricted Cash, Current of $0 as of 2025-09-30, per its 10-K filed 2025-11-19.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashCurrent · last filed 2025-11-19
- 2025-09-30: Restricted Cash, Current $0.00.
- 2025-06-30: Restricted Cash, Current $0.00.
- 2025-03-31: Restricted Cash, Current $0.00.
- 2024-12-31: Restricted Cash, Current $608.00K.
| Period end | Restricted Cash, Current |
|---|---|
| 2025-09-30 | $0.00 10-K · filed 2025-11-19 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-14 |
| 2024-12-31 | $608.00K 10-Q · filed 2025-02-12 |
| 2024-09-30 | $608.00K 10-K · filed 2025-11-19 |
| 2024-06-30 | $608.00K 10-Q · filed 2024-08-07 |
| 2023-09-30 | $0.00 10-K · filed 2024-11-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |